MCL Literature Feed

This preclinical rat study shows the antifungal posaconazole increases zanubrutinib plasma exposure, highlighting a significant drug-drug interaction that may necessitate dose adjustments in MCL patients to avoid toxicity.

A novel MIPI/CD3 prognostic model using Quantitative Dot Blot to measure T-cell infiltration improves risk stratification, showing high CD3+ T-cells correlate with better outcomes in MCL.

This retrospective study suggests a 1-day bendamustine regimen for MCL offers comparable progression-free survival to the standard 2-day schedule but with significantly less neutropenia and adverse events.

A case of ganciclovir-resistant CMV encephalitis in a pirtobrutinib-treated MCL patient highlights a rare but severe infectious complication, urging vigilance for CNS symptoms with this non-covalent BTKi.

This case report of a non-MCL conjunctival lymphoma notes that MCL is a rare cause, highlighting an uncommon site of extranodal disease for MCL patients.

A case report of an elderly MCL patient with sequential relapses in rare extranodal sites (ocular adnexa, soft tissue, heart) highlights the need for vigilance for unusual disease presentations.

This case report details the rare co-occurrence of MCL and a tubular adenoma within a single colonic polyp, emphasizing the need for pathologists to carefully evaluate lymphoid aggregates in polyps.

This case report highlights how inadequate bone marrow sampling can lead to diagnostic errors, underscoring the critical need for proper technique to ensure accurate MCL staging and diagnosis.

Ibrutinib oral suspension has comparable bioavailability to tablets/capsules and is compatible with enteral tubes, providing a crucial administration option for MCL patients with dysphagia or requiring tube feeding.

This 20-year Taiwanese retrospective study confirms that frontline rituximab, intensive chemotherapy, and autologous transplant are associated with improved survival, validating these established strategies in a real-world Asian cohort.

Spontaneous splenic rupture is a rare but life-threatening initial presentation of MCL, requiring emergency splenectomy which can lead to the diagnosis, as highlighted by this case report.

This CLL study reveals venetoclax rapidly activates a BAFF-driven survival axis in residual tumor cells, a key resistance mechanism potentially targetable in MCL to deepen BCL2i responses.

Epigenetic profiling reveals a unique DNA methylation signature for B-cell prolymphocytic leukemia, providing a novel biomarker to differentiate it from its mimics, including mantle cell lymphoma.

The novel, chemotherapy-free triplet of alisertib, ibrutinib, and rituximab demonstrates clinical activity in MCL, providing a new therapeutic strategy for likely relapsed/refractory patients.

This large retrospective study of 476 MCL patients aged ≥80 provides crucial real-world outcome data, informing treatment selection and expectations in the very elderly population.

This case report illustrates the diagnostic challenge of distinguishing mantle cell lymphoma from chronic lymphocytic leukemia, emphasizing the critical role of specific pathological and cytogenetic markers for accurate diagnosis.

This preclinical study explains bortezomib-induced pulmonary toxicity, showing it increases endothelial RhoA/RhoC proteins, which synergize with inflammation to cause vascular hyperpermeability and capillary leak syndrome.

In newly diagnosed MCL, PET/CT-based bone marrow assessment has greater prognostic value than biopsy and is incorporated into a new MCL-PET-I index for improved risk stratification.

This case report describes a rare MCL CNS relapse presenting as Horner syndrome and oculomotor nerve palsy, highlighting the need for CSF analysis in patients with atypical neurological symptoms, even with normal imaging.

This systematic review of brexu-cel for relapsed/refractory MCL reveals conflicting cost-effectiveness conclusions across different countries, highlighting major uncertainties for health systems considering its adoption and reimbursement.

This general review contextualizes CAR T-cell therapy, including its approved use in mantle cell lymphoma, within the broader landscape of cellular therapies, summarizing its efficacy and common toxicities.

This review highlights that TP53-mutated MCL represents a distinct high-risk entity with poor outcomes to chemoimmunotherapy, underscoring the urgent need for novel, non-chemotherapy frontline approaches in these patients.

Reviewing the TRIANGLE trial, this paper argues that adding ibrutinib to frontline induction makes omitting autologous stem cell transplant consolidation a non-inferior, less toxic option for young patients.

This review outlines the clinical landscape and practical application of CAR-T and bispecific antibodies for relapsed/refractory MCL, guiding their integration into practice after targeted therapy failure.

This case report and literature review details the diagnosis and management of central nervous system involvement in MCL, a rare and aggressive manifestation with a poor prognosis.

This case report of non-nodal CNS MCL mimicking autoimmune or paraneoplastic encephalitis highlights the need to consider lymphoma in the differential diagnosis of complex neurological syndromes.

This review details Bortezomib's multiple anti-cancer mechanisms and significant toxicities, highlighting the need for next-generation proteasome inhibitors with better therapeutic windows for treating mantle cell lymphoma.

This review synthesizes the evolution of BTK-targeted therapies, from covalent inhibitors to non-covalent agents and degraders, outlining current treatment paradigms and future combination strategies for frontline and relapsed MCL.

Reviewing AIM and SYMPATICO trials, the ibrutinib-venetoclax combination shows high efficacy in relapsed/refractory MCL, supporting a potential fixed-duration, MRD-guided treatment strategy.

This review summarizes the clinical development and efficacy of BTK inhibitors in MCL, detailing common resistance mutations and outlining future directions for this crucial targeted therapy class.